Table 2.
Response | |
---|---|
CR (including CRu) | 11 (37%) |
PR | 7 (23%) |
Relapsed disease status | |
CR | 10/25 (40%) |
PR | 6/25 (34%) |
Primary refractory | |
CR | 1/5 (20%) |
PR | 1/5 (20%) |
Survival (median follow‐up 32 months) | |
Overall survival (4‐years) | 28.2% |
Progression‐free survival (4‐years) | 17.5% |
CR, complete response; CRu, complete response uncertain; PR, partial remission.